Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients-Reference-Cited by-同舟云学术

Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients

Published:2019-08-08 Issue:4 Volume:105 Page:e190-e193
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Tanaka Junji,Tanaka Norina,Wang Yan-Hua,Mitsuhashi Kenjiro,Ryuzaki Michiko,Iizuka Yuki,Watanabe Aya,Ishiyama Midori,Shinohara Akihito,Kazama Hiroshi,Hagiwara Shotaro,Yoshinaga Kentaro,Kougen Yumi,Kobayashi Hirohito,Kanno Hitoshi,Shiseki Masayuki

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective;Biomarker Research;2024-07-17

2. Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes;Journal of Immunology Research;2024-02-27

3. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy;Frontiers in Immunology;2023-11-24

4. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment;Frontiers in Immunology;2023-11-08

5. Natural Killer Cell Cellular–Based Therapeutic Options for Management of Acute Myeloid Leukemia: Prospect and Challenges;2023-11-06